Abstract
T cell non-Hodgkin lymphoma (T-NHL) is highly invasive and heterogeneous without accurate prognosis prediction. We proposed peripheral CD16−/CD16 + monocytes the additional indicators for T-NHL prognosis. We prospectively recruited 31 T-NHL patients without previous treatment. The CD16−/CD16 + monocyte ratio before chemotherapy was calculated and regular follow up was performed to calculate prognostic prediction value. Tumor associated macrophages (TAM) in tumor tissue were counted and transcriptome sequencing of CD16− and CD16 + monocytes was applied to explore potential mechanisms. We found that T-NHL patients had higher ratio of total monocytes especially the CD16 + monocytes along with a decreased ratio of CD16−/CD16 + monocytes, compared to the health control. The 1-year overall survival rate was 0.492 and 0.755 for CD16− monocyte/CD16 + monocyte ratio of <11 and ≥11(p < 0.05), respectively. The peripheral CD16−/CD16 + monocyte ratio was significantly relevant with the pathological CD68/CD206 macrophage ratio. The differently expressed genes in CD16− and CD16 + monocytes from T-NHL patients were mainly involved in signaling molecules related to tumor microenvironment. Pro-tumor genes were identified in monocyte subsets especially in CD16 + monocytes. In conclusion, the ratio of peripheral CD16−/CD16 + monocyte helps to stratify the prognosis of T-NHL. The relatively increased CD16 + monocytes may contribute to the pro-tumor microenvironment of T-NHL.
Highlights
T cell lymphoma is one kind of non-Hodgkin’s lymphoma with high incidence in Asia[1]
In a recent study we found for the first time that the lower CD16− monocytes/CD16− monocytes ratio seemed to indicate the worse prognosis of diffuse large B cell lymphoma (DLBCL)[5]
31 T cell lymphoma patients without treatment were enrolled in this study
Summary
T cell lymphoma is one kind of non-Hodgkin’s lymphoma with high incidence in Asia[1]. Accurate prediction and evaluation of the prognosis of T-cell non-Hodgkin lymphoma (T-NHL) helps to select the correct treatment strategies to improve the curative effect and survival[2]. Tumor microenvironment especially the tumor-associated macrophage (TAM) has been recognized as a promising predictive marker in lymphoma[4] and peripheral blood monocytes are considered the major sources of TAMs. In a recent study we found for the first time that the lower CD16− monocytes/CD16− monocytes ratio seemed to indicate the worse prognosis of diffuse large B cell lymphoma (DLBCL)[5]. We prostitute CD16−/CD16 + monocytes may reflect tumor microenvironment and may be used to predict the survival of T-NHL In this prospective cohort study, we recruited T-NHL patients to identify the value of peripheral CD16−/ CD16 + monocyte ratio in predicting the survival of T-NHL. The correlation between peripheral monocyte subsets and TAMs in the pathological tissue and the different gene expression profiles of monocyte subsets between the patients and the health were explored in order to reveal the potential mechanisms that monocyte subsets played in the prognosis of T-NHL
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
